StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck total Diabetes Franchise (Januvia + Janumet) — Worldwide sales ($M) ($M)

Form 8-K Supplemental Table 3 Footnote (Total Diabetes sales)

Latest, FY2025
2,862
Period ended Dec 31, 2025
Change on a year earlier
+10.1%
2,599 in FY2024
History
9 years
Since FY2017
Sources
6
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Diabetes Franchise (Januvia + Janumet) — Worldwide sales ($M) ($M)Year on yearSource
FY2025Dec 31, 20252,862+10.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 20242,599-29.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 20233,701-23.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20224,848-13.2%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 20215,584-0.1%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2020Dec 31, 20205,588-2.2%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2019Dec 31, 20195,714-4.7%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 20185,994+1.2%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2017Dec 31, 20175,922–Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Breakdown

What makes up total diabetes franchise (januvia + janumet) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Total Diabetes Franchise (Januvia + Janumet) — Worldwide sales ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_total_diabetes

See every metric in the Merck KPI table. Data updated Oct 26, 2026.